Oct 29, 4:07 PM ET
Merit Medical reported third-quarter 2026 revenue of $416.2 million, up 8.4% from a year earlier, and GAAP EPS of $0.70, up 51%. The company raised its full-year 2026 revenue and non-GAAP EPS guidance, and separately disclosed a $45 million cash acquisition of Solo Pace, Inc.
- Q3 2026 reported revenue $416.2 million, up 8.4%; organic constant currency revenue up 9%
- GAAP gross margin fell to 48.2% from 48.5%; GAAP operating margin rose to 14.1% from 11.1%
- Full-year 2026 non-GAAP EPS guidance raised to $4.33-$4.37 from $4.25-$4.35; revenue guidance to $1.635-$1.642 billion from $1.631-$1.643 billion
- Solo Pace acquisition completed October 13, 2026 for cash of approximately $45 million
Read the filing on SEC.gov ↗
Aug 20, 4:02 PM ET
Merit Medical said it eliminated its Chief Operating Officer position in an August 14, 2026 reorganization and named Sheri Lewis Executive Vice President of Global Operations, effective August 31, 2026. Neil W. Peterson, the former COO, became Senior Advisor and has given notice of resignation for good reason effective March 5, 2027. The filing describes a leadership change in the operations function without any reported financial results.
- Sheri Lewis appointed EVP of Global Operations effective August 31, 2026, with a $600,000 base salary and $400,000 signing bonus
- Lewis's target annual bonus is 60% of base salary, with a maximum of 200%
- Neil W. Peterson's COO title was changed to Senior Advisor; his resignation takes effect March 5, 2027
- Lewis's agreement provides a lump sum of two times salary plus bonus average if terminated without cause or for good reason after a change of control
Read the filing on SEC.gov ↗
Jul 30, 4:13 PM ET
Merit Medical reported second-quarter 2026 revenue of $418.8 million, up 10% from a year earlier, and GAAP diluted EPS of $0.65, up from $0.54. The company raised its full-year 2026 revenue guidance to $1.631 billion to $1.643 billion and its non-GAAP EPS guidance to $4.25 to $4.35, both above its April 30, 2026 outlook. Year-to-date operating cash flow and free cash flow both declined, at $110.0 million (down 11%) and $76.6 million (down 14%).
- Q2 2026 reported revenue $418.8 million, up 10%; constant currency organic revenue up 9%
- GAAP EPS $0.65 vs. $0.54 a year earlier; non-GAAP EPS $1.19, up 18%
- 2026 revenue guidance raised to $1.631-$1.643 billion; non-GAAP EPS guidance raised to $4.25-$4.35 from $4.01-$4.15
- Year-to-date cash flow from operations $110.0 million, down 11%; free cash flow $76.6 million, down 14%
Read the filing on SEC.gov ↗
May 19, 4:54 PM ET
At its annual meeting on May 13, 2026, Merit Medical shareholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan, elected four directors, and ratified Deloitte and Touche LLP as auditor for fiscal 2026. The Board also adopted Fifth Amended and Restated Bylaws effective May 14, 2026. The equity plan reserves a maximum of 2,700,000 shares of common stock for awards, which shareholders should weigh when considering future share issuance.
- Equity Incentive Plan approved with 48,750,003 votes for and 1,510,844 against; maximum share reserve of 2,700,000 shares
- Four directors elected: Martha G. Aronson, Lonny J. Carpenter and Scott R. Ward to 2029 terms; Lynne N. Ward to a 2027 term
- Say-on-pay advisory vote passed with 48,835,995 for and 1,415,355 against
- Fifth A&R Bylaws, effective May 14, 2026, add remote meeting participation, electronic notice and updated universal proxy provisions
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
